ErbB family receptor inhibitors as therapeutic agents in breast cancer: Current status and future clinical perspective

Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer

(2010) Harold J. Burstein et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer

(2010) Kimberly L. Blackwell et al.   JOURNAL OF CLINICAL ONCOLOGY

Chromogenic In Situ Hybridization Is a Reliable Method for DetectingHER2Gene Status in Breast Cancer

(2009) Yun Gong et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Performance of Chromogenic In Situ Hybridization on Testing HER2 Status in Breast Carcinomas With Chromosome 17 Polysomy and Equivocal (2+) HercepTest Results

(2009) Yun Gong et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens

(2009) K. L. Blackwell et al.   ANNALS OF ONCOLOGY

The Potential of PARP Inhibitors in Genetic Breast and Ovarian Cancers

(2009) Yvette Drew et al.   Annals of the New York Academy of Sciences

The prevalence of BRCA1 mutations among young women with triple-negative breast cancer

(2009) SR Young et al.   BMC CANCER

A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors

(2009) K.-K. Wong et al.   CLINICAL CANCER RESEARCH

The emerging potential of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer

(2009) Yvette Drew et al.   CURRENT OPINION IN OBSTETRICS & GYNECOLOGY

Phase I and Pharmacokinetic Study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese Patients with Solid Tumors

(2009) N. Yamamoto et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab for Patients With Axillary-Node–Positive Breast Cancer: Results of the FNCLCC-PACS 04 Trial

(2009) Marc Spielmann et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study

(2009) Gunter von Minckwitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study

(2009) Bella Kaufman et al.   LANCET ONCOLOGY

Triple-negative breast cancer: Novel therapies and new directions

(2009) Sumanta Kumar Pal et al.   MATURITAS

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

(2009) Peter C. Fong et al.   NEW ENGLAND JOURNAL OF MEDICINE

Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer

(2008) I. H. Park et al.   ANNALS OF ONCOLOGY

A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer

(2008) H. J. Burstein et al.   ANNALS OF ONCOLOGY

The Development of HKI‐272 and Related Compounds for the Treatment of Cancer

(2008) Allan Wissner et al.   ARCHIV DER PHARMAZIE

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

(2008) David Cameron et al.   BREAST CANCER RESEARCH AND TREATMENT

Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancer

(2008) Rupert Bartsch et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A Phase II Trial of Erlotinib in Combination with Bevacizumab in Patients with Metastatic Breast Cancer

(2008) M. N. Dickler et al.   CLINICAL CANCER RESEARCH

Phase II Study of Predictive Biomarker Profiles for Response Targeting Human Epidermal Growth Factor Receptor 2 (HER-2) in Advanced Inflammatory Breast Cancer With Lapatinib Monotherapy

(2008) Stephen Johnston et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer

(2008) Henry L. Gomez et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer

(2008) Angelo Di Leo et al.   JOURNAL OF CLINICAL ONCOLOGY

Novel therapies in breast cancer: what is new from ASCO 2008

(2008) David Chu et al.   Journal of Hematology & Oncology

Engineered Cystine-Knot Peptides that Bind αvβ3 Integrin with Antibody-Like Affinities

(2008) Adam P. Silverman et al.   JOURNAL OF MOLECULAR BIOLOGY

Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy

(2008) X. Li et al.   JNCI-Journal of the National Cancer Institute

EGFR Antagonists in Cancer Treatment

(2008) Fortunato Ciardiello et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeted Therapies for the Treatment of Breast Cancer in the Post-trastuzumab Era

(2008) F. Petrelli et al.   ONCOLOGIST

Trastuzumab in the Adjuvant Treatment of Early-Stage Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

(2008) I. J. Dahabreh et al.   ONCOLOGIST

The Role of Selective Estrogen Receptor Modulators on Breast Cancer: From Tamoxifen to Raloxifene

(2008) Wen-Ling Lee et al.   Taiwanese Journal of Obstetrics & Gynecology

Systematic Review of HER2 Breast Cancer Testing

(2008) Marta Cuadros et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY